08 Aug PAOLO RIZZARDI, MD
Paolo Rizzardi, MD, internist, is co-Founder, Chairman&CEO of Altheia Science, a clinical-ready SME developing innovative gene therapy approaches in autoimmunity and cancer. He combines a strong scientific background with managerial skills gained in substantially contributing to successfully develop biotechnology companies and to achieve the market approval of advanced therapy medicinal products in the cell&gene therapy and oncology field. After spending more than 10 years in academia in Italy, UK, and Switzerland in developing programs for innovative immune-based/vaccination strategies in patients with HIV/AIDS, he has worked for more than 20 years in the cell&gene therapy biotech sector, developing a unique expertise in R&D, CMC, clinical and business development, development, engineering, and IP from target validation to market approval. He is co-Founder of AurorA-TT, a technology transfer initiative focused in the biotech sector.
He published over 90 peer-reviewed manuscripts and textbook chapters (6000+ citations, h-index 36), including seminal contribution to the field of gene therapy and HIV infection.